Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement

نویسندگان

  • Christoph Lange
  • Ibrahim Abubakar
  • Jan-Willem C. Alffenaar
  • Graham Bothamley
  • Jose A. Caminero
  • Anna Cristina C. Carvalho
  • Kwok-Chiu Chang
  • Luigi Codecasa
  • Ana Correia
  • Valeriu Crudu
  • Peter Davies
  • Martin Dedicoat
  • Francis Drobniewski
  • Raquel Duarte
  • Cordula Ehlers
  • Connie Erkens
  • Delia Goletti
  • Gunar Günther
  • Elmira Ibraim
  • Beate Kampmann
  • Liga Kuksa
  • Wiel de Lange
  • Frank van Leth
  • Jan van Lunzen
  • Alberto Matteelli
  • Dick Menzies
  • Ignacio Monedero
  • Elvira Richter
  • Sabine Rüsch-Gerdes
  • Andreas Sandgren
  • Anna Scardigli
  • Alena Skrahina
  • Enrico Tortoli
  • Grigory Volchenkov
  • Dirk Wagner
  • Marieke J. van der Werf
  • Bhanu Williams
  • Wing-Wai Yew
  • Jean-Pierre Zellweger
  • Daniela Maria Cirillo
چکیده

The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) substantially challenges TB control, especially in the European Region of the World Health Organization, where the highest prevalence of MDR/XDR cases is reported. The current management of patients with MDR/XDR-TB is extremely complex for medical, social and public health systems. The treatment with currently available anti-TB therapies to achieve relapse-free cure is long and undermined by a high frequency of adverse drug events, suboptimal treatment adherence, high costs and low treatment success rates. Availability of optimal management for patients with MDR/XDR-TB is limited even in the European Region. In the absence of a preventive vaccine, more effective diagnostic tools and novel therapeutic interventions the control of MDR/XDR-TB will be extremely difficult. Despite recent scientific advances in MDR/XDR-TB care, decisions for the management of patients with MDR/XDR-TB and their contacts often rely on expert opinions, rather than on clinical evidence. This document summarises the current knowledge on the prevention, diagnosis and treatment of adults and children with MDR/XDR-TB and their contacts, and provides expert consensus recommendations on questions where scientific evidence is still lacking.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Beyond multidrug-resistant tuberculosis in Europe: a TBNET study.

The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe. We evaluated second-line drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrug-resistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any f...

متن کامل

The Tuberculosis Network European Trials Group (TBNET): new directions in the management of tuberculosis

The Tuberculosis Network European Trials Group (TBNET) is the largest clinical research organisation in Europe. Educational activities include the TBNET Academy and the European Advanced Course in Clinical Tuberculosis. Four of their publications are reviewed to show how the clinical management of tuberculosis is changing. KEY POINTS Most tuberculosis (TB) in contacts is found at their first ...

متن کامل

Variation in policy and practice of adolescent tuberculosis management in the WHO European Region

in Children. 2nd Edn. WHO/HTM/TB/2014.03. Geneva, World Health Organization, 2014. http://apps.who.int/ medicinedocs/documents/s21535en/s21535en.pdf 6 Bonnet M, Bastard M, du Cros P, et al. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study. Int J Tuberc Lung Dis 2016; 20: 177–186. 7 Pontali E, Sotgiu G, D’Ambrosio L, et al. Bedaquiline a...

متن کامل

A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis.

Linezolid is used to treat patients with multidrug-resistant (MDR)/extensively drug-resistant (XDR)-tuberculosis (TB) cases, although clinical data on its safety, tolerability and efficacy are lacking. We performed a retrospective, nonrandomised, unblinded observational study evaluating the safety and tolerability of linezolid at 600 mg q.d. or b.i.d. in MDR/XDR-TB treatment in four European co...

متن کامل

Study of HIV seroprevalence in Pulmonary Tuberculosis Patients with Special Reference to Multidrug Resistant Mycobacteria

This study was planned to determine HIV seroprevalence among pulmonary tuberculosis patients, to characterize the isolated mycobacteria into typical and atypical strains and to evaluate the drug resistant pattern of mycobacterial isolates. The study aims to correlate multidrug resistance (MDR) and HIV seropositivity status in pulmonary tuberculosis patients. During the year 1994-1997, 750 pulmo...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 44  شماره 

صفحات  -

تاریخ انتشار 2014